Women who started hormone therapy early after menopause saw a significant slowing of atherosclerotic progression, whereas those who waited more than a decade saw no impact on vascular health
You are receiving this e-mail because you subscribed to the Special Reports email list. If you no longer wish to receive this newsletter, click here. |   | News and Information for Healthcare Professionals | Thursday, December 4, 2014 | |  Menopausal HRT Timing Hypothesis Affirmed in CVD
Women who started hormone therapy early after menopause saw a significant slowing of atherosclerotic progression, whereas those who waited more than a decade saw no impact on vascular health, the ELITE trial showed, supporting the "timing hypothesis." FULL STORY»
Genes Predict Thombotic Risk
Double or triple positivity for antiphospholipid antibodies (aPL) doubles the risk of a thrombotic event compared with carriers of single positivity or the healthy population at large, according to Finnish researchers. In a prospective nationwide cohort study, all aPL carriers who had a thrombotic event had autoimmune disease. FULL STORY» |  | |  | © 2014 Everyday Health, Inc. All rights reserved. Use of this site constitutes acceptance of MedPage Today's terms of use and privacy policy. The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.
MEDPAGE TODAY, EXPERT PATIENT, MEDPAGE TODAY MOBILE, ADD YOUR KNOWLEDGE, PUTTING BREAKING MEDICAL NEWS INTO PRACTICE and TEACHING BRIEF are registered trademarks of MedPage Today and Everyday Health, Inc. | You have received this email because you have registered to receive alert emails at www.medpagetoday.com, with the email address: kostikblog@ukr.net.
Change ALL email settings | Instant Unsubscribe from "Special Reports" | TECHNICAL QUESTIONS: webmaster@medpagetoday.com
MedPage Today, LLC. - 345 Hudson Street, 16th Floor. New York, NY 10014 Tel: 646.728.9500 - Fax: 646.728.9501 |
|
